The PPAR-gamma Pro12Ala polymorphism and risk of cognitive impairment in a longitudinal study

Neurobiology of Aging

Volumn 31, Issue 5, 2010, Pages 741-746

  West, Nancy A ^a,b   Haan, Mary N ^a   Morgenstern, Hal ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Cognitive impairment; Dementia; Pro12Ala genotype

Indexed keywords

ALANINE; APOLIPOPROTEIN E4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE;

AGED; ARTICLE; BODY MASS; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE;

AGED; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MEXICAN AMERICANS; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; RISK FACTORS; SEX FACTORS;

EID: 77950541928     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.06.005     Document Type: Article

References (31)

1. Altshuler D., Hirschhorn J.N., Klannemark M., Lindgren C.M., Vohl M.C., Nemesh J., Lane C.R., Schaffner S.F., Bolk S., Brewer C., Tuomi T., Gaudet D., Hudson T.J., Daly M., Groop L., Lander E.S. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 2000, 26:76-80.
2. Buzzetti R., Petrone A., Ribaudo M.C., Alemanno I., Zavarella S., Mein C.A., Maiani F., Tiberti C., Baroni M.G., Vecci E., Arca M., Leonetti F., Mario U.D. The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity. Eur. J. Hum. Genet. 2004.
3. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 1994, 7:180-184.
4. Cossrow N., Falkner B. Race/ethnic issues in obesity and obesity-related comorbidities. J. Clin. Endocrinol. Metab. 2004, 89:2590-2594.
5. Craft S., Asthana S., Schellenberg G., Cherrier M., Baker L.D., Newcomer J., Plymate S., Latendresse S., Petrova A., Raskind M., Peskind E., Lofgreen C., Grimwood K. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 1999, 70:146-152.
6. Craft S., Peskind E., Schwartz M.W., Schellenberg G.D., Raskind M., Porte D. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998, 50:164-168.
7. Gonzalez H.M., Mungas D., Reed B.R., Marshall S., Haan M.N. A new verbal learning and memory test for English- and Spanish-speaking older people. J. Int. Neuropsychol. Soc. 2001, 7:544-555.
8. Grootenhuis P.A., Snoek F.J., Heine R.J., Bouter L.M. Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet. Med. 1994, 11:253-261.
9. Haan M.N. Therapy insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat. Clin. Pract. Neurol. 2006, 2:159-166.
10. Haan M.N., Mungas D.M., Gonzalez H.M., Ortiz T.A., Acharya A., Jagust W.J. Prevalence of dementia in older latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. J. Am. Geriatr. Soc. 2003, 51:169-177.
11. Hara K., Okada T., Tobe K., Yasuda K., Mori Y., Kadowaki H., Hagura R., Akanuma Y., Kimura S., Ito C., Kadowaki T. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem. Biophys. Res. Commun. 2000, 271:212-216.
12. Jorm A.F., Jacomb P.A. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol. Med. 1989, 19:1015-1022.
13. Kalmijn S., Feskens E.J., Launer L.J., Stijnen T., Kromhout D. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995, 38:1096-1102.
14. Koivisto A.M., Helisalmi S., Pihlajamaki J., Hiltunen M., Koivisto K., Moilanen L., Kuusisto J., Helkala E.L., Hanninen T., Kervinen K., Kesaniemi Y.A., Laakso M., Soininen H. Association analysis of peroxisome proliferator-activated receptor gamma polymorphisms and late onset Alzheimer's disease in the Finnish population. Dement. Geriatr. Cogn. Disord. 2006, 22:449-453.
15. Kuusisto J., Koivisto K., Mykkanen L., Helkala E.L., Vanhanen M., Hanninen T., Kervinen K., Kesaniemi Y.A., Riekkinen P.J., Laakso M. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 1997, 315:1045-1049.
16. Laakso M. Insulin resistance and coronary heart disease. Curr. Opin. Lipidol. 1996, 7:217-226.
17. Launer L.J. Diabetes and brain aging: epidemiologic evidence. Curr. Diab. Rep. 2005, 5:59-63.
18. Luchsinger J.A., Tang M.X., Shea S., Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63:1187-1192.
19. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
20. Mori H., Ikegami H., Kawaguchi Y., Seino S., Yokoi N., Takeda J., Inoue I., Seino Y., Yasuda K., Hanafusa T., Yamagata K., Awata T., Kadowaki T., Hara K., Yamada N., Gotoda T., Iwasaki N., Iwamoto Y., Sanke T., Nanjo K., Oka Y., Matsutani A., Maeda E., Kasuga M. The Pro12→Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001, 50:891-894.
21. Mori Y., Kim-Motoyama H., Katakura T., Yasuda K., Kadowaki H., Beamer B.A., Shuldiner A.R., Akanuma Y., Yazaki Y., Kadowaki T. Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem. Biophys. Res. Commun. 1998, 251:195-198.
22. Peila R., Rodriguez B.L., White L.R., Launer L.J. Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 2004, 63:228-233.
23. Razay G., Wilcock G.K. Hyperinsulinaemia and Alzheimer's disease. Age Ageing 1994, 23:396-399.
24. Sauder S., Kolsch H., Lutjohann D., Schulz A., von Bergmann K., Maier W., Heun R. Influence of peroxisome proliferator-activated receptor gamma gene polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients. J. Neural Transm. 2005, 112:1381-1389.
25. Scacchi R., Pinto A., Gambina G., Rosano A., Corbo R.M. The peroxisome proliferator-activated receptor gamma (PPAR-gamma2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians. Brain Res. 2007.
26. Stefanski A., Majkowska L., Ciechanowicz A., Frankow M., Safranow K., Parczewski M., Moleda P., Pilarska K. Association between the Pro12Ala variant of the peroxisome proliferator-activated receptor-gamma2 gene and increased 24-h diastolic blood pressure in obese patients with type II diabetes. J. Hum. Hypertens 2006.
27. Teng E.L., Chui H.C. The modified mini-mental state (3MS) examination. J. Clin. Psychiatry 1987, 48:314-318.
28. Tierney M.C., Black S.E., Szalai J.P., Snow W.G., Fisher R.H., Nadon G., Chui H.C. Recognition memory and verbal fluency differentiate probable Alzheimer disease from subcortical ischemic vascular dementia. Arch. Neurol. 2001, 58:1654-1659.
29. Yaffe K., Kanaya A.M., Lindquist K., Hsueh W.C., Cummings S.R., Beamer B., Newman A., Rosano C., Li R., Harris T. PPAR-gamma Pro12Ala genotype and risk of cognitive decline in elders. Neurobiol. Aging 2006.
30. Yen C.J., Beamer B.A., Negri C., Silver K., Brown K.A., Yarnall D.P., Burns D.K., Roth J., Shuldiner A.R. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem. Biophys. Res. Commun. 1997, 241:270-274.
31. Zietz B., Barth N., Spiegel D., Schmitz G., Scholmerich J., Schaffler A. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 (PPARgamma2) is associated with higher levels of total cholesterol and LDL-cholesterol in male caucasian type 2 diabetes patients. Exp. Clin. Endocrinol. Diabetes 2002, 110:60-66.